Volume : 13, Issue : 04, April – 2026

Title:

IN-VITRO AND IN-VIVO EVALUATION OF NOVEL ANTICANCER MOLECULES TARGETING HER2 RECEPTOR

Authors :

Sakshi Janardhan Godase, Tejas Lalasaheb Gaikwad, Samruddhi Shivaji Kondubhairy, Alpesh Ankush Chavan, Dr. Rahul Ishwara Jadhav

Abstract :

The overexpression of the HER2 receptor has been identified as a critical driver in the pathogenesis and progression of several aggressive cancers, particularly breast, gastric, and ovarian malignancies. Targeting HER2 has revolutionized cancer therapy by enabling the development of highly specific treatment strategies that improve therapeutic efficacy while minimizing systemic toxicity. This review comprehensively summarizes the biological significance of HER2, its role as a therapeutic target, and the current landscape of HER2-targeted therapies, including monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates.
Furthermore, the review highlights the importance of in-vitro and in-vivo evaluation methods for assessing the efficacy, safety, and mechanism of action of novel HER2-targeting molecules. In-vitro approaches such as cytotoxicity assays, mechanistic studies, and molecular analyses provide essential insights into drug–cell interactions and signaling inhibition. In-vivo studies, including animal models, pharmacokinetic and pharmacodynamic assessments, and toxicity evaluations, offer a more comprehensive understanding of therapeutic performance under physiological conditions.
Despite significant advancements, challenges such as drug resistance, tumor heterogeneity, and adverse effects continue to limit the long-term success of existing therapies. Therefore, the development of novel anticancer molecules and advanced drug delivery systems remains crucial. This review emphasizes the need for integrated preclinical evaluation strategies and innovative therapeutic approaches to enhance the effectiveness of HER2-targeted cancer treatment and improve patient outcomes.
Keywords: HER2 receptor, HER2-positive cancer, Targeted therapy, Monoclonal antibodies, Tyrosine kinase inhibitors, Antibody–drug conjugates, In-vitro evaluation, In-vivo studies.

Cite This Article:

Please cite this article in press Alpesh Ankush Chavan et al., In-Vitro And In-Vivo Evaluation Of Novel Anticancer Molecules Targeting Her2 Receptor., Indo Am. J. P. Sci, 2026; 13(04).

REFERENCES:

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science. 1987;235(4785):177–182.
2. Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.
3. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463–475.
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137.
5. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469–6487.
6. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9(1):16–32.
7. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8(6):215.
8. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734.
9. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791.
10. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621.
11. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine in HER2-positive breast cancer. N Engl J Med. 2006;355(26):2733–2743.
12. Rabindran SK. Antitumor activity of HER-2 inhibitors. Cancer Lett. 2005;227(1):9–23.
13. Olayioye MA. Update on HER2 as a target for cancer therapy. Oncogene. 2001;20(58):7827–7832.
14. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–354.
15. Ross JS, Fletcher JA. The HER2/neu oncogene in breast cancer. Oncologist. 1998;3(4):237–252.
16. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for HER2 testing in breast cancer. J Clin Oncol. 2013;31(31):3997–4013.
17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy. N Engl J Med. 2005;353(16):1659–1672.
18. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–1283.
19. Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415–2429.
20. Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135(1):55–62.
21. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies. J Clin Oncol. 2012;30(17):2039–2047.
22. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in gastric cancer. Lancet. 2010;376(9742):687–697.
23. Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in gastric cancer. Lancet. 2020;396(10251):165–175.
24. Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37(4):496–513.
25. Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers. Cancer Treat Rev. 2019;78:102–110.
26. Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, et al. HER2-mediated internalization of cytotoxic agents. Cancer Discov. 2020;10(5):674–687.
27. Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, et al. Neratinib in HER2-positive breast cancer. Lancet Oncol. 2018;19(12):1688–1700.
28. Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine vs treatment of physician’s choice. Lancet Oncol. 2014;15(7):689–699.
29. Barok M, Isola J, Pályi-Krekk Z, Nagy P, Juhász I, Vereb G, et al. Trastuzumab induces ADCC. J Immunol. 2007;179(3):1581–1589.
30. Scaltriti M, Baselga J. EGFR/HER2 pathway. Clin Cancer Res. 2006;12(18):5268–5272.
31. Mosmann T. Rapid colorimetric assay for cellular growth (MTT). J Immunol Methods. 1983;65(1-2):55–63.
32. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. SRB assay. J Natl Cancer Inst. 1990;82(13):1107–1112.
33. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, et al. Anticancer drug screening. Cancer Res. 1988;48(17):4827–4833.
34. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. Annexin V apoptosis assay. J Immunol Methods. 1995;184(1):39–51.
35. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. Flow cytometry apoptosis detection. J Immunol Methods. 1991;139(2):271–279.
36. Towbin H, Staehelin T, Gordon J. Western blotting. Proc Natl Acad Sci USA. 1979;76(9):4350–4354.
37. Livak KJ, Schmittgen TD. RT-PCR analysis. Methods. 2001;25(4):402–408.
38. Engvall E, Perlmann P. ELISA development. Immunochemistry. 1971;8(9):871–874.
39. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Animal research guidelines. Br J Cancer. 2010;102(11):1555–1577.
40. Kerbel RS. Tumor xenograft models. Nat Rev Cancer. 2003;3(1):1–9.
41. Bibby MC. Orthotopic models. Nat Rev Cancer. 2004;4(5):401–410.
42. Chou TC. Drug synergy. Pharmacol Rev. 2006;58(3):621–681.
43. Gibaldi M, Perrier D. Pharmacokinetics principles. J Pharm Sci. 1982;71(7):749–750.
44. Danhof M, de Jongh J, De Lange EC. PK/PD modeling. Eur J Pharm Sci. 2007;30(3-4):181–193.
45. Torchilin VP. Multifunctional nanocarriers. Nat Rev Drug Discov. 2005;4(2):145–160.
46. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers. Nat Nanotechnol. 2007;2(12):751–760.
47. Allen TM, Cullis PR. Liposomal delivery. Science. 2004;303(5665):1818–1822.
48. Duncan R. Polymer therapeutics. Nat Rev Cancer. 2006;6(9):688–701.
49. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. EPR effect. J Control Release. 2000;65(1-2):271–284.
50. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. DESTINY-Breast03. N Engl J Med. 2022;387:9–20.
51. Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan vs T-DM1. N Engl J Med. 2022;386(12):1143–1154.
52. Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-low breast cancer. Nat Rev Clin Oncol. 2020;17(9):567–584.
53. Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. CLEOPATRA trial. Lancet Oncol. 2020;21(4):519–530.
54. Gradishar WJ. HER2 therapy evolution. J Clin Oncol. 2020;38(15):1782–1788.
55. Denkert C, Seither F, Schneeweiss A, et al. Biomarkers in HER2 therapy. Ann Oncol. 2015;26(12):2403–2410.
56. Arteaga CL. HER2-targeted therapy resistance. Clin Cancer Res. 2010;16(20):4909–4912.
57. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer therapy advances. Lancet. 2021;397(10286):1750–1769.
58. Emens LA. Breast cancer immunotherapy. Nat Rev Clin Oncol. 2018;15(3):159–174.
59. Lambert JM, Morris CQ. ADCs in cancer therapy. Adv Ther. 2017;34(5):1015–1035.
60. Beck A, Goetsch L, Dumontet C, Corvaia N. ADC review. Nat Rev Drug Discov. 2017;16(5):315–337.
61. Carter PJ, Senter PD. ADC development. Cancer J. 2008;14(3):154–169.
62. Chari RVJ. Targeted cancer therapy. Acc Chem Res. 2008;41(1):98–107.
63. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2023;73(1):17–48.
64. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2021;71(3):209–249.
65. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer burden. CA Cancer J Clin. 2018;68(6):394–424.
66. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer epidemiology. CA Cancer J Clin. 2015;65(2):87–108.
67. Baselga J. HER2 targeted therapy. Oncology. 2011;25(7):1–8.
68. Slamon DJ. HER2 in cancer therapy. Semin Oncol. 2001;28(5):1–8.
69. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis HER2. J Clin Oncol. 2010;28(1):92–98.
70. Hudis CA. HER2 therapeutic strategies. Oncologist. 2007;12(6):630–639.
71. Giordano SH. HER2-positive breast cancer treatment. Cancer. 2013;119(17):3037–3044.
72. Perez EA. HER2 testing and treatment. Breast Cancer Res. 2014;16(3):1–10.
73. Burstein HJ. HER2 targeted therapy review. J Clin Oncol. 2015;33(17):1975–1982.
74. Krop IE. T-DM1 review. Clin Cancer Res. 2017;23(15):3455–3460.
75. Modi S. ADC therapy. Cancer Discov. 2020;10(5):674–687.
76. Cortes J. HER2 therapy advances. Lancet. 2018;391(10116):263–274.
77. Waks AG, Winer EP. Breast cancer therapy. JAMA. 2019;321(3):288–300.
78. Swain SM. Dual HER2 blockade. Oncologist. 2013;18(1):115–124.
79. Tolaney SM. Novel HER2 agents. Clin Adv Hematol Oncol. 2021;19(2):1–10.
80. Dent S, Oyan B, Honig A, Mano M, Howell S. HER2 cardiotoxicity. Breast. 2013;22:S173–S179.